-
Mashup Score: 4AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease - 3 month(s) ago
Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement - 3 month(s) ago
New post-hoc analysis demonstrated efficacy of RINVOQ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: New post-hoc data of #atopicdermatitis in the head and neck region was presented today at the #EADVCongress alongside other impactful research. Read more: https://t.co/k7ewbkiwhu https://t.co/6gWVigmAOq
-
-
Mashup Score: 4AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer - 3 month(s) ago
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: The @EMA_News' #CHMP announced a positive opinion for our investigational medicine for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant #OvarianCancer. Read more: https://t.co/IUmsb5jSOU https://t.co/j6qWgwozZX
-
-
Mashup Score: 2AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs - 4 month(s) ago
Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) expressing…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: New data showcasing progress from our ADC program will be presented at #ESMO24. Learn more about the advancement of our #SolidTumors R&D in tumor types with high unmet needs: https://t.co/ZAxNlSYPJ3 https://t.co/VxIAZv8LGY
-
-
Mashup Score: 0“Blood Cancer, Explained”: Episode 4 - 4 month(s) ago
In the fourth installment of our ongoing “Blood Cancer, Explained” video series, we were joined by our global advocacy partner Acute Leukemia Advocates Network (ALAN) to discuss the complexity…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
It’s important for those living with #AML and their caregivers to have access to resources throughout the care journey. See more in the latest episode of our “Blood Cancer, Explained” series with @AcuteLeuk: https://t.co/6uT8gXqGta https://t.co/v1FkHsscIp
-
-
Mashup Score: 5
TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: The @EU_Commission has granted conditional marketing authorization in relapsed/refractory follicular #lymphoma, a form of #BloodCancer, after two or more lines of prior therapy, developed with @Genmab. Learn more: https://t.co/MB5ZpYKpr3 https://t.co/EgICA83RHU
-
-
Mashup Score: 7AbbVie Completes Acquisition of Cerevel Therapeutics - 5 month(s) ago
Cerevel’s clinical-stage assets complement AbbVie’s emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson’s disease Emraclidine, a potential…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: @CerevelTx is now part of AbbVie. Together, we're committed to deliver meaningful change for patients living with #neurological and #psychiatric conditions, where unmet needs remain. Learn more: https://t.co/Ehuo8DeFIJ $ABBV https://t.co/WszxZ6OsAv
-
-
Mashup Score: 4
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: The @EMA_News approved our latest treatment for adults with moderately to severely active #UlcerativeColitis. Learn more: https://t.co/76e5p57k9W #IBD https://t.co/EChjyu0k0q
-
-
Mashup Score: 9AbbVie Reports Second-Quarter 2024 Financial Results - 5 month(s) ago
Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: Our Q2 2024 #FinancialResults are in. Learn more: https://t.co/Tgt4UNDaKg $ABBV #earnings https://t.co/k5MUEMAuWv
-
-
Mashup Score: 14AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer - 6 month(s) ago
AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: Today, we announced that Roopal Thakkar has been appointed Chief Scientific Officer for AbbVie. Roopal will lead our R&D organization of more than 14,000 team members as we discover and develop future breakthrough medicines for patients. Learn more: https://t.co/HvmEAljCXm https://t.co/jlq101wLOI
-
NEWS: Today we announced positive topline results from our pivotal Phase 3 trial for our investigational treatment in #ParkinsonsDisease. Learn more: https://t.co/4NPx9ceP9R https://t.co/j4KK29Jj7P